In a resolution to an antitrust investigation, the European Commission announced on Thursday that it has levied fines totaling 13.4 million euros ($14.1 million) against five pharmaceutical companies.
The companies penalized for their involvement in a cartel that sought to manipulate the minimum pricing of an essential ingredient used in the production of the abdominal antispasmodic drug Buscopan and its generic counterparts include Alkaloids of Australia, Alkaloids Corporation, Boehringer, Linnea, and Transo-Pharm.
